Alzheimer's disease is the most common type of dementia among older adults in ageing populations, and the pathological changes that occur before symptoms appear are too extensive; therefore, the focus of research has shifted from late-stage treatment to prevention. This paper investigates whether the low chronic-disease burden in Blue Zone populations can serve as a starting point for prevention-oriented research on neurodegeneration and, as a mechanistic case study, uses resveratrol. First, the literature on the Blue Zone has been evaluated as an observational, hypothesis-generating system rather than a controlled natural experiment, and the proposed path connecting peripheral inflammatory burden to central nervous system immune activity has been set up hypothetically. Next, the neuroinflammatory cascade of Alzheimer's disease is presented, including amyloid-beta and tau pathology, nuclear factor kappa B signalling, cytokine release and oxidative stress, as well as a self-amplifying feedback mechanism among these factors. Resveratrol is a known Sirtuin 1 activator that suppresses various harmful factors, such as the accumulation of amyloid and tau phosphorylation, glial cell activation, reduced antioxidant capacity, impaired insulin signalling, mitochondrial dysfunction, and so on. Although human trials have shown that resveratrol can reach the central nervous system and alter some biomarkers, there have been no corresponding cognitive benefits; instead, an unexplained decrease in brain volume and severe bioavailability limitations have occurred. Resveratrol is thus best understood as a typical representative of the all-around prevention system rather than as the cause of Blue Zone longevity or an independent treatment.